RecruitingNot ApplicableNCT06643715

Research of the Application of Pancreatic Cancer Screening Artificial Intelligence Model "PANDAPro"

Research of the Application of Pancreatic Cancer Screening Artificial Intelligence Model 'PANDAPro': A Single-Center,Realworld Clinical Trial


Sponsor

Zhejiang University

Enrollment

100,000 participants

Start Date

Nov 18, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to build upon the previously developed deep learning-based non-contrast CT pancreatic cancer screening model, PANDA. The model will first undergo training and enhancement, followed by external validation across multiple centers. Subsequently, a large-scale real-world validation will be conducted at Zhejiang University's First Affiliated Hospital , the study will be divided into two rounds. In the first round, the performance of the PANDA model and the upgraded PANDA Pro model will be compared on consecutive retrospective real-world CT scans. In the second round, physicians will record the PANDA Pro results in real time to identify potential pancreatic lesions that may have been clinically missed. By leveraging clinical big data across different scenarios at Zhejiang University's First Affiliated Hospital, the study aims to validate the model's role in prompting and supplementing the diagnosis of PDAC in clinical practice, thereby laying the foundation for large-scale opportunistic screening of PDAC.


Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing an AI model called PANDAPro that analyzes CT scans to detect possible pancreatic cancer earlier than standard methods. You may be eligible if: you are between 18 and 90 years old and have had a chest or abdominal CT scan at a clinic or hospital. You may NOT be eligible if: your CT scan did not include the pancreas area; the scan was done as an emergency without contrast dye; you have had surgery that changed the shape of your abdomen; the scan quality was poor; your CT was ordered by a specialist already investigating a pancreatic mass; you have another active cancer; or you cannot be followed up over time. Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEPANDA Pro

Patients with PANDA Pro-reported PDAC positivity but no pancreatic lesions indicated in the imaging report, or those with positive pancreatic findings in the imaging report but no subsequent clinical intervention, will be identified as requiring follow-up. These patients will be recalled to the First Affiliated Hospital of Zhejiang University for further examination and diagnosis.


Locations(1)

the First Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06643715


Related Trials